Company
Alterity Therapeutics Limited
ASX:ATH
Clinical-stage biotech developing disease-modifying drugs for neurodegenerative disease. Lead candidate ATH434 is an oral small molecule designed to reduce excess iron accumulation in the brain and inhibit aggregation of alpha-synuclein, the protein implicated in Multiple System Atrophy and related synucleinopathies. It targets the underlying biology of age-related neurodegeneration rather than symptoms, which is the longevity-relevant part. ATH434 has completed a randomised placebo-controlled Phase 2 trial in MSA plus an open-label Phase 2 in advanced MSA, and the company is working toward a pivotal Phase 3. It is a single-asset, pre-revenue developer, so exposure is binary on that program.
At a glance
- Listing
- ASX:ATH
- Category
- ASX listed
- Headquarters
- Melbourne, Victoria, Australia
- Market cap
- Not disclosed
Thesis
Why it is in this universe
- Category
- ASX listed
- Market
- Australia
- Recent inflection
- 19 May 2026: Alterity presented Phase 2 ATH434 data at three meetings (ISMRM, MDSANZ, MSA Symposium at UCL), reporting a significant effect at 50 mg twice daily on functional decline (-4.0 points, p=0.035, roughly 48% slowing) and reduced swallowing decline (p=0.003 at 50 mg). The company also reported two positive Type C interactions with the US FDA and said it was on track for an End-of-Phase 2 FDA meeting around mid-2026 to enable a pivotal Phase 3.
- Services
- None recorded
- People tracked
- None on file
Market data
Listing and scale
| Metric | Detail |
|---|---|
| Exchange | ASX |
| Ticker | ASX:ATH |
| Secondary listing | NASDAQ |
| Market cap | Not disclosed |
| Status | Listed and trading |
Editor's noteA listing or financing event is not a clinical result. variis grades evidence on the linked protocol, not the share price.
Get in touch
Contact
- Address
- Melbourne, Victoria, Australia
- Website
- www.globenewswire.com
- Phone
- No public number published
- No public address published
Offering
What it sells today
No commercial services are recorded for this company yet.
Recent inflection
What moved lately
19 May 2026: Alterity presented Phase 2 ATH434 data at three meetings (ISMRM, MDSANZ, MSA Symposium at UCL), reporting a significant effect at 50 mg twice daily on functional decline (-4.0 points, p=0.035, roughly 48% slowing) and reduced swallowing decline (p=0.003 at 50 mg). The company also reported two positive Type C interactions with the US FDA and said it was on track for an End-of-Phase 2 FDA meeting around mid-2026 to enable a pivotal Phase 3.
Common questions
- Why does variis track Alterity Therapeutics Limited?
- Clinical-stage biotech developing disease-modifying drugs for neurodegenerative disease. Lead candidate ATH434 is an oral small molecule designed to reduce excess iron accumulation in the brain and inhibit aggregation of alpha-synuclein, the protein implicated in Multiple System Atrophy and related synucleinopathies. It targets the underlying biology of age-related neurodegeneration rather than symptoms, which is the longevity-relevant part. ATH434 has completed a randomised placebo-controlled Phase 2 trial in MSA plus an open-label Phase 2 in advanced MSA, and the company is working toward a pivotal Phase 3. It is a single-asset, pre-revenue developer, so exposure is binary on that program.
- Is Alterity Therapeutics Limited publicly listed?
- Yes. It trades as ASX:ASX:ATH. variis records the listing, not a live price.
- Where is Alterity Therapeutics Limited based?
- Melbourne, Victoria, Australia
- Is Alterity Therapeutics Limited still trading?
- Alterity Therapeutics Limited is recorded as actively trading.
Keep reading
Related coverage from the newsroom.
Sources
What this profile is built on
- Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy · GlobeNewswire
- Alterity Therapeutics details 2026 EGM results, Form 6-K · StockTitan
- Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy · BioSpace
Every entity profile on variis is sourced. Not investment advice.